Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer

被引：0
|
作者：
Struss, Werner J. [1 ]
Black, Peter C. [1 ]
机构：
[1] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC, Canada
来源：
UROLOGY | 2017年 / 109卷
关键词：
THERAPY;
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1 / 2
页数：2
相关论文
共 50 条
  • [41] Treatment Intensification Patterns and Utilization in Patients with Metastatic Castration-Sensitive Prostate Cancer
    Heath, Elisabeth, I
    Dyson, Gregory E.
    Cackowski, Frank C.
    Hafron, Jason
    Powell, Isaac
    CLINICAL GENITOURINARY CANCER, 2022, 20 (06) : 524 - 532
  • [42] Triplet therapy for metastatic castration-sensitive prostate cancer: Rationale and clinical evidence
    Suzuki, Hiroyoshi
    Akamatsu, Shusuke
    Shiota, Masaki
    Kakiuchi, Haruka
    Kimura, Takahiro
    INTERNATIONAL JOURNAL OF UROLOGY, 2025, 32 (03) : 239 - 250
  • [43] Interstitial Lung Disease Caused by Apalutamide for Metastatic Castration-Sensitive Prostate Cancer
    del Castillo-Acuna, Rocio
    Serradilla, Ana
    Lopez-Campos, Fernando
    Counago, Felipe
    ARCHIVOS DE BRONCONEUMOLOGIA, 2024, 60 (08): : 537 - 538
  • [44] The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited
    Deek, Matthew P.
    Van der Eecken, Kim
    Phillips, Ryan
    Parikh, Neil R.
    Velho, Pedro Isaacsson
    Lotan, Tamara L.
    Kishan, Amar U.
    Maurer, Tobias
    Boutros, Paul C.
    Hovens, Christopher
    Abramowtiz, Matthew
    Pollack, Alan
    Desai, Neil
    Stish, Bradley
    Feng, Felix Y.
    Eisenberger, Mario
    Carducci, Michael
    Pienta, Kenneth J.
    Markowski, Mark
    Paller, Channing J.
    Antonarakis, Emmanuel S.
    Berlin, Alejandro
    Ost, Piet
    Tran, Phuoc T.
    EUROPEAN UROLOGY, 2021, 80 (05) : 632 - 640
  • [45] A cost-utility analysis of apalutamide for metastatic castration-sensitive prostate cancer
    Parmar, Ambica
    Timilshina, Narhari
    Emmenegger, Urban
    Smoragiewicz, Martin
    Sander, Beate
    Alibhai, Shabbir
    Chan, Kelvin K. W.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2022, 16 (03): : E126 - E131
  • [46] PRESCRIPTION PATTERNS OF SYSTEMIC THERAPY IN THE MANAGEMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
    Black, Joseph
    Einstein, David
    Gao, Xin
    Wei, Xiao
    Connell, Brendan
    Kamkari, Nick
    Gershman, Boris
    Olumi, Aria
    JOURNAL OF UROLOGY, 2023, 209 : E123 - E123
  • [47] Balancing efficacy and financial toxicity in the management of metastatic castration-sensitive prostate cancer
    Sridhar, Srikala S.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2019, 13 (12): : 404 - 405
  • [48] Current status and future perspective on the management of metastatic castration-sensitive prostate cancer
    Blas, Leandro
    Shiota, Masaki
    Eto, Masatoshi
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 32
  • [49] Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer
    Matsubara, Nobuaki
    de Bono, Johann
    Sweeney, Christopher
    Chi, Kim N.
    Olmos, David
    Sandhu, Shahneen
    Massard, Christophe
    Garcia, Josep
    Chen, Geng
    Harris, Adam
    Schenkel, Fanny
    Sane, Rucha
    Hinton, Healther
    Bracarda, Sergio
    Sternberg, Cora N.
    CLINICAL GENITOURINARY CANCER, 2023, 21 (02) : 230 - +
  • [50] Abiraterone acetate plus prednisolone treatment beyond prostate specific antigen and radiographic progression in metastatic castration-resistant prostate cancer patients
    Biro, Krisztina
    Budai, Barna
    Szonyi, Marta
    Kuronya, Zsofia
    Gyergyay, Fruzsina
    Nagyivanyi, Krisztian
    Geczi, Lajos
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (02) : 81.e1 - 81.e7
12345